Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph W Chow

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Biological Chemistry|January 23, 2009
Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferasesMarta Toth, Joseph W Chow, Shahriar Mobashery, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2010
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicinMarta Toth, Hilary Frase, Joseph W Chow, et al.
Antimicrobial Agents and Chemotherapy|June 18, 2025
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patientsRujia Xie, Halley Rogers, Joseph W Chow, et al.
The Journal of Biological Chemistry|January 18, 2008
Aminoglycoside 2''-phosphotransferase type IIIa from EnterococcusAdriana Badarau, Qicun Shi, Joseph W Chow, et al.
Biochemistry|April 12, 2007
Kinetic mechanism of enterococcal aminoglycoside phosphotransferase 2"-IbMarta Toth, Jaroslav Zajicek, Choonkeun Kim, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Mutations in the aph(2")-Ic gene are responsible for increased levels of aminoglycoside resistanceHae Kyung Lee, Sergei B Vakulenko, Don B Clewell, et al.
Drug Safety|July 1, 2020
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial ProgrammeKaren Cheng, Paul Newell, Joseph W Chow, et al.
International Journal of Antimicrobial Agents|August 15, 2006
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Po-Ren Hsueh, Theresa A Snyder, Mark J Dinubile, et al.
Surgical Infections|January 26, 2006
In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)Joseph W Chow, Vilas Satishchandran, Theresa A Snyder, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infectionsMark J DiNubile, Joseph W Chow, Vilas Satishchandran, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Biological Chemistry|January 23, 2009
Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferasesMarta Toth, Joseph W Chow, Shahriar Mobashery, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2010
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicinMarta Toth, Hilary Frase, Joseph W Chow, et al.
Antimicrobial Agents and Chemotherapy|June 18, 2025
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patientsRujia Xie, Halley Rogers, Joseph W Chow, et al.
The Journal of Biological Chemistry|January 18, 2008
Aminoglycoside 2''-phosphotransferase type IIIa from EnterococcusAdriana Badarau, Qicun Shi, Joseph W Chow, et al.
Biochemistry|April 12, 2007
Kinetic mechanism of enterococcal aminoglycoside phosphotransferase 2"-IbMarta Toth, Jaroslav Zajicek, Choonkeun Kim, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Mutations in the aph(2")-Ic gene are responsible for increased levels of aminoglycoside resistanceHae Kyung Lee, Sergei B Vakulenko, Don B Clewell, et al.
Drug Safety|July 1, 2020
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial ProgrammeKaren Cheng, Paul Newell, Joseph W Chow, et al.
International Journal of Antimicrobial Agents|August 15, 2006
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Po-Ren Hsueh, Theresa A Snyder, Mark J Dinubile, et al.
Surgical Infections|January 26, 2006
In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)Joseph W Chow, Vilas Satishchandran, Theresa A Snyder, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infectionsMark J DiNubile, Joseph W Chow, Vilas Satishchandran, et al.
Pageof 4